JNC 8: Relaxing the Pressure in the Hypertension Guidelines
|
|
|
- Bertram Wilkinson
- 9 years ago
- Views:
Transcription
1 JNC 8: Relaxing the Pressure in the Hypertension Guidelines Ashley Lawrance, Pharm.D. PGY1 Pharmacy Practice Resident Peninsula Regional Medical Center Salisbury, MD
2 Learning Objectives Describe updated recommendations for blood pressure control from JNC 8 panel members in the 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Compare these updated recommendations for target blood pressure goals with: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Other national and international organization guidelines on hypertension Identify controversies surrounding the 2014 update on hypertension management Develop treatment plan for patients with hypertension utilizing recommendations from the 2014 update on hypertension management
3 Case 1 DB, a 38 y/0 African American female with stage III chronic kidney disease, presents to her primary care physician with persistently elevated blood pressure despite initiating life style changes about 3 months ago. Her blood pressure during today s visit was 156/98. The physician has decided to initiate an antihypertensive agent for DB. He is thinking of sending DB home with a prescription for Lisinopril 5 mg to be titrated and consults you for recommendations. Is Lisinopril an appropriate option? If not, what agent do you recommend for DB?
4 Case 2 PL is a 61 yr old Caucasian male who has recently suffered from an ischemic stroke. His current blood pressure 168/95 and he has not been on blood pressure medications before. The physician would like to start PL on antihypertensive medications. Which of the following agents do you recommend for PL? A. Hydrocholorthiazide + ramipril B. Chlorthalidone alone C. Metoprolol + losartan D. Diltiazem alone
5 High Blood Pressure Defined as an abnormal elevation of blood pressure 140/90 1 in 3 adults in the US have hypertension Only about 47% of people with hypertension have it controlled Prevalence by age: 45 years men > women years men = women 65 years men < women Prevalence by Race African Americans 44.3% Mexican Americans 28.4% Caucasians 32.6% Centers for Disease Control and Prevention. High Blood Pressure.
6 Causes of High Blood Pressure Essential hypertension Secondary hypertension Sleep apnea Drug-induced Chronic kidney disease Primary aldosteronism Chronic steroid therapy or Cushing s syndrome Pheochomocytoma Coarctation of the aorta Thyroid or parathyroid disease
7 Drug-Induced HTN Amphetamines Antidepressants Corticosteroids Calcineurin inhibitors Decongestants Ergot alkaloids Erythropoietin stimulating agents Estrogen-containing oral contraceptives NSAIDS
8 Risks High blood pressure increases risk of: Heart failure Myocardial ischemia and infarction Stroke Aneurysms and dissection Kidney disease Retinopathy Peripheral vascular disease
9 Adults 18 years or older with HTN JNC 7 Summary Algorithm Implement lifestyle modifications Not at goal BP (<140/90 or < 130/90 for patients with diabetes or CKD) Initial Drug Choices No compelling Indications (Target: <140/90) Stage 1 HTN: Thiazide #1, may consider ACEI/ARB/BB/ CCB or combo Stage 2 HTN: 2- drug combo for most, thiazide + ACEI/ARB/BB/ CCB Compelling Indications (Target:<140/90 or <130/80 if DM or CKD) DM: ACEI/ ARB #1 (may add diuretic, BB, CCB) CKD: ACEI/ ARB MI: BB, then add ACEI/ ARB (may add Aldo ANT) HF: Diuretic + ACEI, then add BB (may add Aldo ANT or ARB) CAD: BB, then add ACEI/ ARB (may add CCB or diuretic) Stroke: diuretic + ACEI
10 JNC 8
11 Course of Development March 2008 the National Heart Lung and Blood Institute (NHLBI) established the panel for the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) January 2013, the guideline was submitted for external peer review to 20 reviewers with expertise in hypertension, primary care, cardiology, nephrology, and other important related fields. (Comments reviewed by the Panel from March through June 2013) June 2013, NHLBI withdrew from process Instead partner with selected organizations: American Heart Association (AHA), the American College of Cardiology (ACC) August 2013, process to release guidelines under the auspices of the AHA and ACC failed Panel elected to pursue publication as an independent panel (December 2013)
12 Questions Guiding JNC 8 1. In adults with hypertension, does initiating antihypertensive pharmacologic therapy at specific blood pressure thresholds improve health outcomes? 2. In adults with hypertension, does treatment with antihypertensive pharmacologic therapy to a specified blood pressure goal lead to improvements in health outcomes? 3. In adults with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes?
13 Classification of Recommendations Based on critical review of high quality randomized controlled trials Classification of recommendations: (A) Strong Recommendation: high certainty based on evidence that the net benefit is substantial (B) Moderate Recommendation: moderate certainty based on evidence that the net benefit is moderate to substantial (C) Weak Recommendation: at least moderate certainty based on evidence that there is a small net benefit (D) Recommendation against: at least modest certainty based on evidence that there is no net benefit or that risks/harms outweigh benefits (E) Expert Opinion: Net benefit is unclear because there is insufficient evidence but this is what the committee recommends. Further research is necessary.
14 Summary of Recommendations General Population 60 yrs Initiate Tx at BP 150/90 mmhg (Grade A) Target BP < 150/90 mmhg (Grade A) Corollary: if BP achieved is lower than target and well tolerated, no adjustments needed to Tx (Grade E) General Population < 60 yrs Initiate Tx at BP 140/90 mmhg Target BP < 140/90 mmhg Diastolic goal: (30-59 yearsà Grade A; yearsà Grade E) Systolic goal: (Grade E) Population 18 yrs with CKD or DM Initiate Tx at BP 140/90 (Grade E) Target BP < 140/90 (Grade E)
15 Summary of Recommendations General nonblack population ± DM Initial Tx should include thiazide-type diuretic, CCB, ACEI, or ARB (Grade B) General black population ± DM Initial Tx should include a thiazide-type duretic or CCB (General black population à Grade B; black population w/dmà Grade C) Entire population 18 yrs with CKD Initial or add-on Tx should include an ACEI or ARB (Grade B)
16 Summary of Recommendations If BP goal not reached within 1 mo of Tx, increase dose of initial drug or add a second agent If goal still not reached with two agents titrated up, third agent from the recommended list (i.e. thiazidetype diuretic, CCB, ACEI/ARB)may be added Following third agent, if goal still not reached, refer to a specialist. Can add antihypertensive agents from other classes Do not use ACEI and ARB together
17 JNC 8: Update Summary Algorithm
18
19 JAMA. 2014;311(5): doi: /jama "
20 AHA/ACC/CDC Science Advisory Go A S et al. Hypertension. 2014;63:
21 Response to JNC 8: Minority Report Minority (5/17) of the panel disagreed with recommendation to increase target SBP from 140 to 150 mm Hg in persons > 60 years without DM or CKD. 1. Reduce intensity of antihypertensive treatment in groups at highest risk for cardiovascular disease (CVD) African Americans Patients with CVD Patients with multiple CVD risk factors other than DM or CKD 2. Evidence supporting increase was insufficient and inconsistent with the evidence supporting other recommendations 3. The higher SBP goal may reverse the decades-long decline in CVD, especially stroke mortality.
22 Other Controversies No longer sanctioned by NHLBI or other agencies like AHA and ACC Discrepancies and lack of consensus between guidelines Raising target BP in highest risk group for CDV disease (age > 60) may lead to greater events
23 Case 1 DB, a 38 y/0 African American female with stage III chronic kidney disease, presents to her primary care physician with persistently elevated blood pressure despite initiating life style changes about 3 months ago. Her blood pressure during today s visit was 156/98. The physician has decided to initiate an antihypertensive agent for DB. He is thinking of sending DB home with a prescription for Lisinopril 5 mg to be titrated and consults you for recommendations. Is Lisinopril an appropriate option? If not, what agent do you recommend for DB? 61 y/o with recent stroke
24 Case 2 PL is a 61 yr old Caucasian male who has recently suffered from an ischemic stroke. His current blood pressure 168/95 and he has not been on blood pressure medications before. The physician would like to start PL on antihypertensive medications. Which of the following agents do you recommend for PL? A. Hydrocholorthiazide + ramipril B. Chlorthalidone alone C. Metoprolol + losartan D. Diltiazem alone
Special Communication
Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National
ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
Treatment of Hypertension: JNC 8 and More
PL Detail-Document #300201 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Treatment of
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
Antihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT
Antihypertensive Drug Management to Achieve Systolic Blood Pressure
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
Diabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
Hypertension and Heart Failure Medications. Dr William Dooley
Hypertension and Heart Failure Medications Dr William Dooley Plan Heart Failure Acute vs. chronic Mx Hypertension Common drugs used Method of action Choice of medications Heart Failure Aims; Short term:
Epidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613
Epidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613 1 Definition Hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. 2 Primary
HYPERTENSION: Comparison of New Guidelines
HYPERTENSION: Comparison of New Guidelines L. Brian Cross, PharmD, BCACP, CDE Vice-Chair & Associate Professor Bill Gatton College of Pharmacy Department of Pharmacy Practice Associate Professor James
Cardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
Combination Antihypertensive Therapy: When to use it Diabetes
Combination Antihypertensive Therapy: When to use it Diabetes George L. Bakris, MD, F.A.S.N., F.A.S.H. Professor of Medicine Director, ASH Comprehensive Hypertension Center The University of Chicago Medicine
HYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
Hypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
From Concept to Rapid Visualization a Data Analytics Case Study
From Concept to Rapid Visualization a Data Analytics Case Study Gregory Wozniak, PhD Director of Outcomes Analytics Health Outcomes Group American Medical Association The Journey Objectives Share experiences
Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
March 7, 2014 Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Dear Sir or Madam: On behalf of the American Heart Association (AHA), including the American Stroke
Hypertension Guidelines
Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not
Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1
Chronic Kidney Disease (CKD) Algorithm Chronic Kidney Disease (CKD) Algorithm Page 1 Chronic Kidney Disease (CKD) Algorithm (See NICE Clinical Guideline CG73 1 and Quality Standards 2 ) Who should have
Guidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
African Americans & Cardiovascular Diseases
Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age
Drug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW
Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)
Renovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
CASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
Hypertension Guideline V4
Hypertension Guideline V4 Approved 24/06/2008 Version VERSION 4 FINAL Date of First Issue 26/02/08 Review Date 01/03/2010 Date of Issue 24/06/2008 EQIA Yes / No 24/06/2008 Author / Contact Dr Leslie Cruickshank
Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
Correspondence to: Rima B Shah ([email protected]) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care
Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of patients
Most probable Diagnosis
Most probable Diagnosis Evidence from monitoring Blood Pressure Measured using home monitoring device weekly 165 Peak reading 150 Average reading 130 Min reading Evidence from EMR Family history of Essential
Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD
Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION ISPOR 2013 WORKSHOP
Hypertension in Chronic Kidney Disease Vito M. Campese, MD
Hypertension in Chronic Kidney Disease Vito M. Campese, MD Professor of Medicine, Physiology and Biophysics Division of Nephrology and Hypertension Center Co-Director USC/UKRO Kidney Research Center Keck
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
The practice of lowering blood pressure (BP)
Original Paper Treatment of Hypertension in the Inpatient Setting: Use of Intravenous Labetalol and Hydralazine Alan B. Weder, MD; 1 Steven Erickson, PharmD 2 Acute blood pressure elevations are commonly
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie [email protected] 1
Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie [email protected] 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und
Guideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
Rx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
Absolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
Main Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE
Riociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
Anticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
Quiz 5 Heart Failure scores (n=163)
Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the
High Blood Pressure (Essential Hypertension)
Sacramento Heart & Vascular Medical Associates February 18, 2012 500 University Ave. Sacramento, CA 95825 Page 1 916-830-2000 Fax: 916-830-2001 What is essential hypertension? Blood pressure is the force
PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
Heart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
Evaluation of anti-hypertensive drug utilisation and cost in Hospital Tengku Ampuan Afzan, Kuantan.
Evaluation of anti-hypertensive drug utilisation and cost in Hospital Tengku Ampuan Afzan, Kuantan. Azarisman SMS a,e, Aszrin A b, Sahimi M d, Ngow HA a,e, Marzuki AO a, Jamalludin AR c, Sapari S d and
Case Study 6: Management of Hypertension
Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular
Renal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology
Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology The chart below lists the measures (and specialty exclusions) that eligible providers must demonstrate
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
MIND-BODY THERAPIES FOR HYPERTENSION
MIND-BODY THERAPIES FOR HYPERTENSION Systematic Review and Meta-Analysis Ather Ali, ND, MPH (1), David L. Katz, MD, MPH (1,2), Michael B. Bracken, PhD, MPH (2). (1)Yale-Griffin Prevention Research Center
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
Hypertension Best Practices Symposium
essentia health: east region 1 Hypertension Best Practices Symposium RN Hypertension Management Pilot Essentia Health: East Region Duluth, MN ORGANIZATION PROFILE Essentia Health is an integrated health
Understanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
Diabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
Easy or complex? University Pharmacy. Pharm.D. candidates, 2011
High Blood Pressure Easy or complex? University Pharmacy Edwin Elliot, Insia Hussain Pharm.D. candidates, 2011 The evolution of mankind 2.5 mn years 50 years and we wonder why our healthcare costs are
Coronary Heart Disease (CHD) Brief
Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
The Hypertension Treatment Center
Patricia F. Kao MD MS Asst Professor, EVMS Nephrology & HTN April 26, 2014 The Hypertension Treatment Center I have no conflicts of interest to disclose Objectives Describe the role of Hypertension Treatment
Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
